ARTL today
$2.12-$0.06 (-2.75%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourBearish
15 minBearish
5 minStrong Bearish
Daily trend turns up above $15.73
Key levels
Resistance$3.45
Resistance$2.42
Support$2.05
Latest news & SEC filings
EarningsArtelo Biosciences Q3 EPS Loss Narrows to $(3.19) From $(88.80) YoY
ProductArtelo Biosciences to share ART27.13 findings at IASP 2026 pain congress
All ARTL news →About Artelo Biosciences
Artelo Biosciences develops prescription medicines that act on fat-based signaling systems in the body, including the endocannabinoid network. Its main programs are ART27.13 for appetite and weight loss in cancer patients, ART26.12 for nerve pain caused by chemotherapy and other conditions, and ART12.11, a CBD-based compound for anxiety and mood disorders. The company is based in California and runs operations in North America and Europe.
Based on the company's 10-K filed Feb 24, 2026.
Nasdaq · Healthcare
ARTELO BIOSCIENCES, INC. (ARTL)
What Is the Price Target for ARTL?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is ARTL a Buy or Sell Right Now?
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ARTL.
Start Free Trial →Is ARTL Overvalued or Undervalued?
Valuation Verdict
N/A
Methods Used
N/A
Fair Value
$N/A
0
Moat Score
NONE
1/9
Piotroski Score
-46.0
Altman Z-Score
What Is Smart Money Doing with ARTL?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ARTL Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
31.58%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for ARTL
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ARTL, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:53:17 | $2.18 | 1,000 | $$2K | BUY |
| 18:36:19 | $2.25 | 1,200 | $$3K | BUY |
| 15:15:22 | $2.17 | 1,000 | $$2K | BUY |
| 15:15:15 | $2.15 | 1,900 | $$4K | SELL |
| 15:14:36 | $2.15 | 1,500 | $$3K | SELL |
5 dark pool trades shown · $$14K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for ARTELO BIOSCIENCES, INC. (ARTL) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ARTL — frequently asked questions
What is ARTL stock price today?
ARTELO BIOSCIENCES, INC. (ARTL) is at $2.12, down 2.75% (-$0.06) at the Nov 12, 2026 close.
Why is ARTL stock moving today?
Latest ARTL news — Nov 12, 2026: Artelo Biosciences Q3 EPS Loss Narrows to $(3.19) From $(88.80) YoY · Oct 29, 2026: Artelo Biosciences to share ART27.13 findings at IASP 2026 pain congress
Why did ARTL stock move on Oct 26, 2026?
Artelo Biosciences announced it will present findings on its ART26.12 non-opioid pain candidate at a pain conference scheduled for October 26 to 30, with accumulating evidence supporting the drug's promise ahead of a planned multiple ascending dose trial. Despite this positive news, ARTL shares fell 10.40% to close at $2.24, trading between a high of $2.50 and a low of $2.15 on volume of 71,605.
Did ARTL beat earnings?
ARTL last reported on Aug 12, 2026: EPS -$8.01 vs -$6.48 expected — a miss of 23.6%.
What is ARTL's P/E ratio?
ARTL trades at a P/E of 0.2 vs a Healthcare average of 17.7.
Does ARTL pay a dividend?
ARTL does not currently pay a dividend.
What are ARTL support and resistance levels?
Support: $2.05. Resistance: $2.42, $3.45, $5.34.
What are insiders doing with ARTL?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on ARTL?
Nov 12, 2026: Artelo Biosciences Q3 EPS Loss Narrows to $(3.19) From $(88.80) YoY · Oct 29, 2026: Artelo Biosciences to share ART27.13 findings at IASP 2026 pain congress